Please assess the completion status of the following clinical trial:

Trial Title: Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and Females aged between 18 and 75 years (included)~2. Pittsburgh Sleep Quality Index (PSQI) score ≥ 5~3. Diagnosed for breast, lung or colon-rectal cancer~4. Metastatic first chemotherapy line~5. Planned duration of chemotherapy treatment at least 63 days~6. Negative to pregnancy test~7. Patients able to swallow~Exclusion Criteria:~1. Known hypersensitivity reaction to Melatonin, Zinc or Magnesium or any components of the product~2. Known current drug or alcohol abuse.~3. Use of other investigational drug(s) within 30 days before study entry or during the study~4. Clinically significant findings on physical examination or presence of known clinically significant disease that would interfere with study evaluation~5. Patients treated with benzodiazepines, hypnotic, anticonvulsant, antipsychotic or antidepressant drugs in the two months before screening visit~6. Patients receiving or planned to receive warfarin~7. Chronic treatment with steroids with daily dose over 10 mg prednisone or equivalent product~8. Brain metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Somnage (Type: EXPERIMENTAL): Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration o.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).